Description
A potent and selective, orally bioavailable alpha4 integrin (alpha4beta1/VLA-4 and, to a lesser extent, alpha4beta7 integrin) antagonist, an ester prodrug of CT-7758; is developed for the treatment of multiple sclerosis. Multiple Sclerosis Phase 2 Discontinued